Klaipedos Nafta
5.3.2021 08:02:04 CET | Globenewswire | Press release
The preliminary sales revenue of the Company’s oil terminals for February 2021 comprises EUR 1.3 million and is lower by EUR 0.8 million or by 38.1 % compared to February of 2020. The preliminary sales revenue of the Company’s oil terminals for the two months of 2021 comprises EUR 3.6 million and is lower by 12.2 % compared to the same period of 2020.
The preliminary sales revenue of the Company’s Klaipėda LNG terminal for February 2021 comprises EUR 2.7 million (during the same month of 2020 – EUR 3.6 million). Klaipėda LNG terminal revenue from regulated activities consists of the regasification tariff fixed part (for booked annual capacities), variable part for amount of re-gasified LNG and reloading revenue. The level of Klaipėda LNG terminal revenue (for booked annual capacities) does not depend on regasification volume. Revenue is confirmed by the National Energy Regulatory Council (NERC) based on the approved methodology of State regulated prices in the natural gas sector and is calculated for the whole upcoming year. The preliminary sales revenue of Klaipėda LNG terminal for the two months of 2021 decreased by 25.3 % compared to the same period of 2020. The main reasons for the lower revenue are both due to lower regasification volumes during first two months of 2021, compared to the same period last year, and because of proportionate reduction of security supplement in 2021, based onthe surplus of LNG return from the period 2014-2019, which was established for the regulated activities of the Company, and is equal to EUR 1.9 million.
The preliminary sales revenue of the Company’s commercial LNG activity for February 2021 comprises EUR 0.2 million and is lower by EUR 0.1 million or by 33.3 % compared to February of 2020. The preliminary sales revenue is higher due to the decrease in consultations of business development projects compared to the same period of 2020. The preliminary sales revenue of the Company’s commercial LNG activity for the two months of 2021 comprises EUR 0.5 million.
Total preliminary sales revenue of the Company for January-February 2021 amounts to EUR 10.0 million and is lower by 20.6 % compared to the same period of 2020 – EUR 12.6 million.
Preliminary revenue of the Company, EUR million:
| February | January - February | |||||
| 2021 | 2020 | Change | 2021 | 2020 | Change | |
| Oil terminals activity | 1.3 | 2.1 | -38.1% | 3.6 | 4.1 | -12.2% |
| LNG terminal activity | 2.7 | 3.6 | -25.0% | 5.9 | 7.9 | -25.3% |
| Commercial LNG activity | 0.2 | 0.3 | -33.3% | 0.5 | 0.6 | -16.7% |
| Total | 4.2 | 6.0 | -30.0% | 10.0 | 12.6 | -20.6% |
Jonas Lenkšas, Chief Financial Officer, +370 694 80594.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Newcap Holdings29.3.2026 12:19:20 CEST | Pressemeddelelse
NewCap Holding A/S har indgået en aftale, betinget af underskrivelse af endelige aftaledokumenter m.v., om erhvervelse af dansk selskab indenfor compliance og risikostyringsservices – Intern viden
Novartis Pharma AG29.3.2026 07:15:00 CEST | Press release
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
Biogen Inc.28.3.2026 20:00:00 CET | Press release
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
MoonLake Immunotherapeutics AG28.3.2026 20:00:00 CET | Press release
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
Sanofi Winthrop Industrie28.3.2026 16:00:00 CET | Press release
Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
